Recent reports have used tranilast to study the role of TRPV2 in macrophage activation and phagocytosis, the progression of dilated cardiomyopathy, and the prevention of right ventricular remodeling and arrhythmias in models of experimental pulmonary hypertension as well as pulmonary endothelial barrier recovery following reactive oxygen species (ROS)-induced permeability, fibrosis development and weight gain in models of non-alcoholic steatohepatitis (NASH), atrial fibrillation, amyloid-β–induced cognitive impairment as well as cancer [17,27,28,29,30,31,32,33,34]. Here, TRPV2 is linked to metabolic dysfunction-associated steatohepatitis.